Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap

Deodhar, Atul; Gensler, Lianne S.; Magrey, Marina; Walsh, Jessica A.; Winseck, Adam; Grant, Daniel; Mease, Philip J.

doi:10.1007/s40744-019-00176-5

Cited by 22 publications

(13 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a result, some of the significant associations identified could be due to shared method variance or social desirability bias. Future researchers should consider using observational measures (e.g., of physical activity or sleep, such as actigraphy [ 69 ]) when possible, to reduce this potential source of bias. Finally, the sample consisted of patients with chronic musculoskeletal pain who were seen in specialty pain clinics.…”

Section: Discussionmentioning

confidence: 99%

The Role of Positive Psychological Factors in the Association between Pain Intensity and Pain Interference in Individuals with Chronic Musculoskeletal Pain: A Cross-Sectional Study

Martínez-Calderón

Flores-Cortes

Clavero-Cano

et al. 2020

JCM

View full text Add to dashboard Cite

This study aimed to test the cross-sectional mediating and moderating role that positive psychological factors play in the association between pain intensity and pain interference in individuals with chronic musculoskeletal pain. A descriptive cross-sectional study using mediation analyses was conducted, including 186 individuals with chronic musculoskeletal pain. We conducted cross-sectional mediation and moderation analyses to determine whether the positive psychological factors mediated or moderated the association between pain intensity and pain interference. Pain acceptance, pain self-efficacy, and optimism were all significantly and weakly related to pain interference when controlling for pain intensity. Pain self-efficacy and pain acceptance partially mediated the association between pain intensity and pain interference. On the other hand, the multiple mediation model did not show significant effects. The three positive psychological factors were not found to significantly moderate the association between pain intensity and pain interference. The findings suggest that in chronic musculoskeletal pain patients, the treatments may focus on [i] what they are capable of doing to manage the pain (i.e., pain self-efficacy) and [ii] being better able to accept the pain as pain waxes and wanes might be also particularly helpful. However, these results must be tested in longitudinal studies before drawing any causal conclusion.

show abstract

Section: Discussionmentioning

confidence: 99%

The Role of Positive Psychological Factors in the Association between Pain Intensity and Pain Interference in Individuals with Chronic Musculoskeletal Pain: A Cross-Sectional Study

Martínez-Calderón

Flores-Cortes

Clavero-Cano

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“… 24 Decreased night pain was also the most significant predictor of improvement in observed Jenkins Sleep Evaluation Questionnaire (JSEQ) scores and improvements in sleep quality significantly correlated with improvements in Short Form-36 (SF-36), BASFI, night back pain, BASDAI, and total back pain scores, as well as in measures of fatigue from the BASDAI and vitality from the SF-36. 25 , 26 …”

Section: Discussionmentioning

confidence: 99%

Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial

Poddubnyy

Pournara

Zielińska³

et al. 2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Background: This study aimed to evaluate the efficacy and safety of secukinumab 150 mg compared with placebo in the management of spinal pain and disease activity in patients with axial spondyloarthritis (axSpA) at Week 8 and up to Week 24. Methods: Patients ( n = 380) with active axSpA were randomized (3:1) to secukinumab 150 mg (Group A) or placebo (Group B). At Week 8, patients from Group A with an average spinal pain score <4 were defined as responders and were re-assigned to secukinumab 150 mg (Arm A1); whereas non-responders were re-randomized to secukinumab 150/300 mg (Arm A2/A3). Patients from Group B were re-randomized (1:1) to secukinumab 150/300 mg (Arm B1/B2). Results: At Week 8, the odds of achieving an average spinal pain score of <4 were significantly higher for patients on secukinumab 150 mg than for patients on placebo (odds ratio (OR): 1.89; 95% confidence interval (CI): 1.08–3.33; p = 0.0264). Further reductions in spinal pain were observed across treatment groups up to Week 24. Pronounced improvements were also observed in other disease activity measurements, such as Bath Ankylosing Spondylitis Disease Activity Index and Ankylosing Spondylitis Disease Activity Score. Responders from Group A showed the highest improvements for all measured parameters of spinal pain compared with the other arms. No new or unexpected safety signals were observed. Conclusion: Secukinumab provided rapid and significant improvement in spinal pain at Week 8 which was sustained or increased further up to Week 24 in patients with axSpA. Trial Registration: ClinicalTrials.gov: NCT03136861. Registered May 2, 2017.

show abstract

“…Sleep is commonly measured in axSpA trials, particularly given that sleep disturbance is associated with the disease (105). Sleep measures are covered in more detail in chapter 20.…”

Section: Sleepmentioning

confidence: 99%

Measuring Outcomes in Axial Spondyloarthritis

Ogdie

Duarte‐García

Hwang

et al. 2020

Arthritis Care & Research

View full text Add to dashboard Cite

Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap

Cited by 22 publications

References 66 publications

The Role of Positive Psychological Factors in the Association between Pain Intensity and Pain Interference in Individuals with Chronic Musculoskeletal Pain: A Cross-Sectional Study

The Role of Positive Psychological Factors in the Association between Pain Intensity and Pain Interference in Individuals with Chronic Musculoskeletal Pain: A Cross-Sectional Study

Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial

Measuring Outcomes in Axial Spondyloarthritis

Contact Info

Product

Resources

About